Nicole M Fischer1,2, Tim O Nieuwenhuis1, Bhuchitra Singh2, Gayane Yenokyan3, James H Segars2. 1. Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Department of Gynecology and Obstetrics, Division of Reproductive Sciences & Women's Health Research, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Biostatistics Center, Johns Hopkins School of Public Health, Baltimore, Maryland.
Abstract
CONTEXT: In vitro and in vivo evidence has supported the role of angiotensin II blockade in reducing leiomyoma cell proliferation and growth. However, no population-based study to date has investigated this potential association. OBJECTIVE: This work aims to determine whether prior angiotensin-converting enzyme inhibitor (ACEi) use is associated with a reduced odds of leiomyoma development. DESIGN: A nested case-control study was conducted. SETTING: The population was assembled from the Truven Health MarketScan Research Database, which includes private health insurance claims from January 1, 2012 to December 31, 2017. PATIENTS OR OTHER PARTICIPANTS: We included (n = 353 917) women age 18 to 65 with hypertension. Cases (n = 13 108) with a leiomyoma diagnosis were matched to controls (n = 340 808) with no such diagnosis at a 1:26 ratio by age and region of origin within the United States. INTERVENTION: Prior ACEi use was determined from outpatient drug claims. MAIN OUTCOME MEASURE: Leiomyoma development was indicated by a first-time diagnosis code. RESULTS: Women on an ACEi experienced a 31.8% reduced odds of developing clinically recognized leiomyoma compared to nonusers (odds ratio [OR] 0.68; 95% CI, 0.65-0.72). This association was significant for each age group: 30 to 39 years (OR 0.86; 95% CI, 0.74-0.99), 40 to 49 years (OR 0.71; 95% CI, 0.66-0.76), 50 to 59 years (OR 0.63; 95% CI, 0.58-0.69), and 60 to 65 years (OR 0.58; 95% CI, 0.50-0.69). Of the ACEis, lisinopril (OR 0.67; 95% CI, 0.64-0.71), quinapril (OR 0.62; 95% CI, 0.41-0.92), and ramipril (OR 0.35; 95% CI, 0.23-0.50) demonstrated a significant association with reduced leiomyoma incidence. CONCLUSIONS: ACEi use was associated with a reduced odds of developing clinically recognized leiomyoma in adult hypertensive women.
CONTEXT: In vitro and in vivo evidence has supported the role of angiotensin II blockade in reducing leiomyoma cell proliferation and growth. However, no population-based study to date has investigated this potential association. OBJECTIVE: This work aims to determine whether prior angiotensin-converting enzyme inhibitor (ACEi) use is associated with a reduced odds of leiomyoma development. DESIGN: A nested case-control study was conducted. SETTING: The population was assembled from the Truven Health MarketScan Research Database, which includes private health insurance claims from January 1, 2012 to December 31, 2017. PATIENTS OR OTHER PARTICIPANTS: We included (n = 353 917) women age 18 to 65 with hypertension. Cases (n = 13 108) with a leiomyoma diagnosis were matched to controls (n = 340 808) with no such diagnosis at a 1:26 ratio by age and region of origin within the United States. INTERVENTION: Prior ACEi use was determined from outpatient drug claims. MAIN OUTCOME MEASURE: Leiomyoma development was indicated by a first-time diagnosis code. RESULTS: Women on an ACEi experienced a 31.8% reduced odds of developing clinically recognized leiomyoma compared to nonusers (odds ratio [OR] 0.68; 95% CI, 0.65-0.72). This association was significant for each age group: 30 to 39 years (OR 0.86; 95% CI, 0.74-0.99), 40 to 49 years (OR 0.71; 95% CI, 0.66-0.76), 50 to 59 years (OR 0.63; 95% CI, 0.58-0.69), and 60 to 65 years (OR 0.58; 95% CI, 0.50-0.69). Of the ACEis, lisinopril (OR 0.67; 95% CI, 0.64-0.71), quinapril (OR 0.62; 95% CI, 0.41-0.92), and ramipril (OR 0.35; 95% CI, 0.23-0.50) demonstrated a significant association with reduced leiomyoma incidence. CONCLUSIONS: ACEi use was associated with a reduced odds of developing clinically recognized leiomyoma in adult hypertensive women.
Authors: Katherine E Hartmann; Howard Birnbaum; Rym Ben-Hamadi; Eric Q Wu; Max H Farrell; James Spalding; Paul Stang Journal: Obstet Gynecol Date: 2006-10 Impact factor: 7.661
Authors: Vasken Dilsizian; William C Eckelman; Maria L Loredo; Elaine M Jagoda; Jamshid Shirani Journal: J Nucl Med Date: 2007-02 Impact factor: 10.057
Authors: T Matsumoto; N Sagawa; M Mukoyama; I Tanaka; H Itoh; M Goto; H Itoh; M Horiuchi; V J Dzau; T Mori; K Nakao Journal: J Clin Endocrinol Metab Date: 1996-12 Impact factor: 5.958
Authors: Woon-Puay Koh; Jian-Min Yuan; Can-Lan Sun; David van den Berg; Adeline Seow; Hin-Peng Lee; Mimi C Yu Journal: Cancer Res Date: 2003-02-01 Impact factor: 12.701
Authors: Ronée E Harvey; Shannon K Laughlin-Tommaso; Elizabeth A Stewart; Jacqueline K Limberg; Timothy B Curry; Michael J Joyner; Jill N Barnes Journal: Physiol Rep Date: 2022-09